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Abstract
This study was carried out to evaluate the effects of selenium supplementation on glycemic control, lipid profiles, and biomarkers of
inflammation and oxidative stress in patients undergoing for coronary artery bypass grafting (CABG) surgery. This randomized,
double-blind, placebo-controlled trial was performed among 33 patients undergoing for CABG surgery, aged 40–85 years old.
Subjects were randomly allocated into two groups to intake either 200 μg/day selenium supplements as selenium yeast (n = 17) or
placebo (n= 16) for 4 weeks. Glycemic control, lipid profiles, and biomarkers of inflammation and oxidative stress were assessed at
baseline and at the end of trial. After the 4-week intervention, selenium supplementation significantly decreased fasting plasma glucose
(FPG) (β, 6.76 mg/dL; 95%CI, − 13.13, − 0.40; P = 0.03), insulin (β, − 1.14 μIU/mL; 95%CI, − 2.01, − 0.28; P = 0.01); homeostasis
model of assessment-estimated insulin resistance (HOMA-IR) (β − 0.35; 95% CI, − 0.62, − 0.08; P = 0.01); and total-/HDL-choles-
terol ratio (β − 0.31; 95% CI, − 0.51, − 0.09; P = 0.008); and significantly increased HDL-cholesterol levels (β, 2.72 mg/dL; 95% CI,
0.89, 4.55; P = 0.005) compared with the placebo. Moreover, selenium supplementation led to a significant reduction in high-
sensitivity C-reactive protein (hs-CRP) (β, − 0.68 mg/L; 95% CI, − 1.18, − 0.17; P = 0.01) and malondialdehyde (MDA) (β, −
0.27 μmol/L; 95% CI, − 0.47, − 0.07; P = 0.009), and a significant elevation in total glutathione (GSH) levels (β, 77.33 μmol/L;
95% CI, 56.11, 98.55; P < 0.001) compared with the placebo. Selenium supplementation did not affect other metabolic profiles.
Overall, our study demonstrated that selenium supplementation for 4 weeks to patients undergoing for CABG surgery had beneficial
effects on FPG, insulin, HOMA-IR, total-/HDL-cholesterol ratio, HDL-cholesterol, hs-CRP, GSH, andMDA levels, but did not affect
other metabolic profiles. Clinical trial registration number: http://www.irct.ir: IRCT2017090533941N22.
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Introduction
Coronary artery bypass grafting (CABG) is a well-accepted
therapeutic approach in people with symptomatic multivessel
coronary artery disease (CAD) [1]. Based on the prior evi-
dence, systemic inflammatory response syndrome, myocardi-
al injury, and organ dysfunction are implicated as the most
important side effects of cardiovascular surgery [2]. In
addition, metabolic disturbances and chronic inflammatory
state were caused by chronic disease in patients undergoing
cardiac procedure contribute to the occurrence of postopera-
tive clinical complications [3]. There is evidence indicating
that a depletion of antioxidative trace elements such as sele-
nium before cardiac operation is associated with a higher in-
cidence of atrial fibrillation and mortality rate following sur-
gery [4, 5]. Increased oxidative damage in cardiac surgery is
accompanied by an additional reduction in the trace elements
concentrations, such as selenium, copper, and zinc and subse-
quent reduction of selenoenzymes which may lead to postop-
erative multiorgan dysfunction [6].
The trace elements including selenium, copper, and zinc are
essential for maintaining the oxidative balance [7]. Cardiac sur-
gery using cardiopulmonary bypass provokes ischemia-
reperfusion-mediated oxidative stress [8]. Antioxidant supple-
mentation before cardiac surgery may prevent arterial fibrillation
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and reduce hospital stay [9]. Bahmani et al. [10] demonstrated
that selenium supplementation for 12 weeks to patients with
diabetic nephropathy had beneficial effects on insulin levels
and insulin resistance, but did not affect fasting glucose, insulin
sensitivity, and lipid profiles. In a meta-analysis conducted by Ju
et al. [11], selenium supplementation to patients with coronary
heart disease (CHD) significantly reduced C-reactive protein
(CRP) levels, and significantly glutathione peroxidase activity.
Moreover, administration of a new conditioning supplement con-
taining selenium, glutamine, L-carnitine, vitamin C, and vitamin
E for 7 days to nondiabetic patients scheduled for CABG led to
better perioperative glycemic control and decreased post-CABG
wound infection [12].
Selenoproteins have different biological functions, including
regulating insulin signaling and glucose metabolism [13]. In ad-
dition, selenium may improve lipid profiles by reducing the ex-
pression of lipogenic enzyme genes [14]. Selenium also modu-
lates the reactive oxygen species (ROS) and inhibits the nuclear
factor-kappa B (NF-κB) pathway which result in decreased ox-
idative damage and suppressed the production of inflammatory
markers [8]. This evidence highlights the significance of seleni-
um supplementation in patients undergoing for CABG surgery.
Therefore, the present study conducted to examine the effects of
selenium supplementation on glucose homeostasis parameters,
lipid profiles, and markers of inflammation and oxidative stress
in patients undergoing for CABG surgery.
Subjects and Methods
Participants
In a randomized, double-blind, placebo-controlled trial, regis-
tered in the Iranian registry of clinical trials (http://www.irct.ir:
IRCT2017090533941N22), this study was conducted at a
cardiology clinic affiliated to Arak University of Medical
Sciences (AUMS), Arak, Iran, between December 2017 and
August 2018. Diagnosis of CAD was conducted based on the
criteria of the American Heart Association [15]. Exclusion
criteria were as follows: consuming selenium supplements
within the last 3 months, having cardiac surgery within the
past 3 months, or significant renal of hepatic failure and
change in the dosage and kind of medications. This
investigation was done according to the principals of the
Declaration of Helsinki and the study protocol was approved
by the ethics committee of AUMS. All patients were informed
about the aims and protocol of the study. Written informed
consent was obtained from all subjects prior to the intervention.
Study Design
At the onset of the study, to decrease potential confounding
effects, all participants were stratified balanced block
randomization. Stratified balanced block randomization with
block size of 4 was used based on the following variables: age
(< 50 vs. ≥ 50 years) and BMI (> 25 vs. ≥ 25 kg/m2). Then,
participants in each block were randomly allocated into two
treatment groups to intake either 200 μg selenium supple-
ments as selenium yeast (n = 17) or placebo (n = 16) per day
for 4 weeks. Patients were requested not to change their rou-
tine physical activity or usual diets throughout the study and
not take any antioxidant medications or supplements during
the 4-week intervention which might affect the results of the
study. Selenium and its placebos were produced by Webber
Naturals Company (Mississauga, Canada) and Barij Essence
Pharmaceutical Company (Kashan, Iran), respectively. Both
selenium supplements and placebos had similar packaging
and patients and researchers were unaware of the content of
the package until the end of study. Randomization assignment
was performed using computer-generated random numbers.
Randomization and allocation were concealed from the inves-
tigators and participants until the final analyses were complet-
ed. The randomized allocation sequence, enrolling partici-
pants, and allocating them to interventions were conducted
by a trained staff member at the clinic. Compliance with the
intake of supplements and placebos was determined by exam-
ining the tablet containers. In addition, participants received a
daily reminder message on their cell phones to take their sup-
plements regularly. All participants completed 3-day dietary
records (two weeks’ days and one-weekend day) at week 1, 2,
and 4 of the trial. The dietary records were based on estimated
values in household measurements. To obtain nutrient intakes
of participants according to 3-day food records, we used
Nutritionist IV software (First Databank, San Bruno, CA)
adopted for the Iranian food pattern. It must be kept in mind
that in this study, we provided 7-day menu cycles to partici-
pants. The diets were planned using a Bcalorie count^ system.
To control for dietary intakes of participants throughout the
study, the dietitian was calling the participants to resolve their
probable problems. All participants spent about 45 min with a
dietitian learning the basics of their diets.
Assessment of Anthropometric Measures
Weight (Seca, Hamburg, Germany) was assessed at baseline
and after the 4-week intervention in cardiology clinic by a
trained staff member. Height (Seca, Hamburg, Germany)
was determined by a nonstretched tape measure to the nearest
0.1 cm. BMI was determined as weight in kg divided by
height in meters squared.
Outcomes
Insulin levels and the homeostasis model of assessment-
insulin resistance (HOMA-IR) were considered as the primary
outcomes and lipid profiles, and biomarkers of inflammation
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and oxidative stress were considered as the secondary out-
comes. Ten milliliters of fasting blood samples were collected
at baseline and after the 4-week intervention at Arak reference
laboratory, Arak, Iran. Fasting plasma glucose (FPG) was
measured on the day of blood collection. Serum insulin levels
were assessed by an ELISA kit (DiaMetra, Milano, Italy) with
inter- and intra-assay coefficient variances (CVs) below 5%.
HOMA-IR and the quantitative insulin sensitivity check index
(QUICKI) were determined according to the standard formula
[16]. Enzymatic kits (Pars Azmun, Tehran, Iran) were applied
to evaluate FPG and lipid profiles with inter- and intra-assay
CVs below 5%. Serum high sensitivity (hs)-CRP levels were
determined by a commercial ELISA kit (LDN, Nordhorn,
Germany) with inter- and intra-assay CVs below 7%. The
plasma nitric oxide (NO) levels were determined using
Griess method [17]. Plasma TAC levels by the method of
ferric reducing antioxidant power developed by Benzie and
Strain [18], total glutathione (GSH) using the method of
Beutler et al. [19], and malondialdehyde (MDA) concentra-
tions by the thiobarbituric acid reactive substances spectro-
photometric test [20] were determined with inter- and intra-
assay CVs below 5%.
Statistical Methods
We used the formula suggested for randomized clinical
trials’ sample size calculation. Type one (α) and type two
errors (β) were defined as 0.05 and 0.20 (power = 80%),
respectively. According to the previous trial [10], we used
1.4 as the SD and 1.12 as the change in mean (d) of
HOMA-IR as a primary outcome.
The Kolmogorov-Smirnov test was done to determine the
normal distribution of variables. To detect differences in an-
thropometric measures and dietary intakes between the two
groups, the independent-samples t test was used. Multiple
linear regression models were used to evaluate treatment ef-
fects on study outcomes after adjusting for confounding pa-
rameters, including baseline values of each biochemical vari-
able, age and BMI. The effect sizes were presented as the
mean differences with 95% confidence intervals. P values <
0.05 were considered significant. The Statistical Package for
Social Science version 18 (SPSS Inc., Chicago, Illinois, USA)
were used for statistical analyses of this trial.
Results
Firstly, we invited 48 participants; however, 8 subjects were
excluded due to not meeting inclusion criteria (Fig. 1). Among
participants in the selenium group, 3 persons (withdrawn due
to personal reasons (n = 3)) and in the placebo group, 4 par-
ticipants (withdrawn due to personal reasons (n = 4)) did not
complete the trial. Finally, 33 participants (selenium (n = 17)
and placebo (n = 16)) completed the trial. The rate of compli-
ance in our study ranged between 90 and 100% in both
groups. No side effects were reported after selenium supple-
mentation in patients undergoing for CABG surgery through-
out the study.
Randomized (n=40) 
Allocated to placebo (n=20) 
Lost to follow-up due to 
personal reasons (n=4) 
Analyzed (n=16) 
Allocated to intervention (n=20) 
Lost to follow-up due to personal 
reasons (n=3) 
Analyzed (n=17) 
Assessed for eligibility (n=48) 
Excluded (n=8)  
- Not meeting inclusion criteria (n=8)  
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Fig. 1 Summary of patient flow
diagram
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Mean age, weight, and BMI at baseline after the 4-week
intervention of study participants were not statistically differ-
ent between selenium and placebo groups (Table 1). In addi-
tion, consumption of antidiabetic and antilipidemic drugs,
consumption of angiontensin-converting enzymes inhibitors
(captopril and enalapril), aldosterone receptor blockers drugs,
and blocker drugs (β- blocker: metoprolol and calcium chan-
nel blocker: amlodipin) at baseline after the 4-week interven-
tion of study participants were not statistically different be-
tween the two groups.
Based on the 3-day dietary records obtained throughout the
intervention, no significant difference was observed between
the two groups in terms ofmicro- andmacronutrients (data not
shown).
After the 4-week intervention, selenium supplementation
significantly decreased FPG (β, 6.76 mg/dL; 95% CI, −
13.13, − 0.40; P = 0.03); insulin (β, − 1.14 μIU/mL; 95% CI,
− 2.01, − 0.28; P = 0.01); HOMA-IR (β, − 0.35; 95% CI, −
0.62, − 0.08; P = 0.01); and total-/HDL-cholesterol ratio (β, −
0.31; 95% CI, − 0.51, − 0.09; P = 0.008); and significantly
increased HDL-cholesterol levels (β, 2.72 mg/dL; 95% CI,
0.89, 4.55; P = 0.005) compared with the placebo (Table 2).
Moreover, selenium supplementation led to a significant re-
duction in hs-CRP (β, − 0.68 mg/L; 95% CI, − 1.18, − 0.17;
P = 0.01) and MDA (β, − 0.27 μmol/L; 95% CI, − 0.47,
−0.07; P = 0.009), and a significant elevation in GSH levels
(β, 77.33μmol/L; 95%CI, 56.11, 98.55;P < 0.001) compared
with the placebo. Selenium supplementation did not affect
other metabolic profiles.
Discussion
In the present study, we found that selenium supplementa-
tion for 4 weeks to patients undergoing for CABG surgery
had beneficial effects on FPG, insulin, HOMA-IR, total-/
HDL-cholesterol ratio, HDL-cholesterol, hs-CRP, GSH
and MDA levels, but did not affect other metabolic
profiles.
Effect on Glycemic Control
CAD is accompanied by metabolic derangement, including
poor glycemic control [21], atherogenic dyslipidemia [22],
inflammatory state, and disrupted antioxidant defense system
[23]. The current study showed that selenium supplementation
for 4 weeks to patients undergoing for CABG surgery signif-
icantly decreased FPG, insulin levels and HOMA-IR, but did
not affect QUICKI score. In a study conducted by Wang et al.
[24], dietary selenium intake was negatively correlated with
insulin resistance. In addition, a 12-week selenium supple-
mentation to subjects with congestive heart failure (CHF) sig-
nificantly reduced insulin concentrations and HOMA-IR, and
significantly increased QUICKI score [25]. Although in pa-
tients with metabolic syndrome, selenium supplementation
was not effective in reducing HOMA-IR [26]. Preoperative
glycemic control can predict insulin sensitivity during cardiac
surgery which is associated with major complications after
surgery [27]. Several pathways involving selenium are known
to influence insulin homeostasis. Seleniummay induce insulin
function by the activation of kinase involved in the insulin
signaling cascade [28]. In addition, selenium increases perox-
isome proliferator activated receptor gamma mRNA expres-
sion which is the key mediator of insulin sensitivity and influ-
ence the glucose and lipid uptake in peripheral tissue [29].
Effect on Lipid Profiles
We found that taking selenium supplements for 4 weeks by
patients undergoing for CABG surgery led to a significant
increase in HDL-cholesterol levels and a significant reduction
in total-/HDL-cholesterol ratio, but did not affect other lipid
profiles. Similarly, our previous study indicated that selenium
supplementation at a dosage of 200 μg/day for 12 weeks to
patients with CHF significantly improved HDL-cholesterol
levels [25]. In addition, long-term treatment with antioxidants
(vitamin C, vitamin E, coenzyme Q10, and selenium) in pa-
tients with multiple cardiovascular risk factors increased
HDL-cholesterol levels, but did not influence other lipid pro-
files [30]. Rayman et al. [31] also reported that 300 μg/day
Table 1 General characteristics
of study participants at baseline
study
Placebo group (n = 16) Selenium group (n = 17) P1
Age (years) 61.2 ± 4.6 62.6 ± 11.6 0.65
Weight at study baseline (kg) 76.6 ± 5.8 76.2 ± 7.8 0.87
Weight at end of trial (kg) 76.5 ± 5.8 76.2 ± 7.7 0.89
Weight change (kg) −0.1 ± 0.6 −0.1 ± 1.2 0.87
BMI at study baseline (kg/m2) 26.2 ± 2.4 26.4 ± 2.9 0.88
BMI at end of trial (kg/m2) 26.2 ± 2.3 26.4 ± 2.9 0.85
BMI change (kg/m2) −0.04 ± 0.2 −0.01 ± 0.4 0.79
Data are mean ± SD
1Obtained from independent t test
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selenium supplementation for 6 months to healthy volunteers
with low selenium levels significantly increased HDL-
cholesterol levels. However, a 3-month selenium supplemen-
tation to hemodialysis patients with selenium deficiency had
no beneficial effect on lipid profiles [32]. HDL-cholesterol
exhibit protective effects on endothelial cells. In addition,
HDL-cholesterol is inversely associated with the risk of myo-
cardial infarction and death [33]. Selenium may increase
HDL-cholesterol levels through positive effect on the expres-
sion of apolipoprotein A-1 expression which provides the
structure to the HDL particle and mediates the esterification
of cholesterol during reverse cholesterol transport [29].
Effect on the Biomarkers of Inflammation
and Oxidative Stress
We found that selenium administration for 4 weeks to patients
undergoing for CABG surgery significantly increased plasma
GSH, and significantly decreased serum hs-CRP and plasma
MDA levels. Consistent with our findings, selenium supple-
mentation to patients with hemodialysis for 3 months signifi-
cantly reduced MDA concentrations [34]. Moreover, seleni-
um supplementation alone or with topiramate for 45 days to
subjects with epilepsy increased erythrocyte GSH levels [35].
In addition, in a meta-analysis conducted by Ju et al. [11],
selenium supplementation to people with CHD significantly
reduced CRP levels. However, a 12-week selenium supple-
mentation to patients with diabetic nephropathy significantly
increased GSH, but did not affect MDA and hs-CRP levels
[36]. Inflammation and oxidative stress are related to the path-
ogenesis of atherosclerosis [37], and increase the risk of post-
operative atrial fibrillation and graft failure [38, 39]. In pa-
tients with cardiac disease, GSH deficiency is associated with
functional status and the structural cardiac abnormalities [40].
In addition, elevated CRP levels are associated with higher
levels of complement protein which predict the development
of atrial fibrillation [41]. Selenoproteins exert a direct inhibi-
tory effect on the binding of NF-κB transcription factor to
DNA through a reversible rupture of disulfide bridge fixation
leading to decreased inflammation [42]. Selenoenzymes also
take part in the cellular defense against oxidative stress
through reducing free radicals and the regeneration of other
antioxidants [28].
The current study had few limitations. The sample size was
small. Future studies with longer duration of the intervention,
and bigger sample size are needed to confirm the validity of
our findings. In addition, we could not evaluate plasma sele-
nium levels before and after the intervention.
Table 2 The effect of selenium supplementation on metabolic status in patients undergoing with coronary artery bypass grafting surgery
Variables Placebo group (n = 16) Selenium group (n = 17) Difference in outcome measures
between selenium and placebo
treatment groups1
Baseline Week 4 Baseline Week 4 β (95% CI) P2
FPG (mg/dL) 120.2 ± 12.3 122.6 ± 14.1 124.5 ± 19.2 120.3 ± 21.1 − 6.76 (− 13.13, − 0.40) 0.03
Insulin (μIU/mL) 12.4 ± 2.1 12.7 ± 2.3 13.0 ± 2.2 12.1 ± 1.9 − 1.14 (− 2.01, − 0.28) 0.01
HOMA-IR 3.7 ± 0.8 3.8 ± 0.9 4.0 ± 1.0 3.7 ± 0.8 − 0.35 (− 0.62, − 0.08) 0.01
QUICKI 0.31 ± 0.007 0.31 ± 0.01 0.31 ± 0.01 0.31 ± 0.01 0.001 (− 0.004, 0.006) 0.65
Triglycerides (mg/dL) 112.7 ± 31.8 114.6 ± 34.5 123.2 ± 50.1 123.8 ± 43.5 − 0.34 (− 8.20, 7.52) 0.93
VLDL-cholesterol (mg/dL) 22.6 ± 6.4 22.9 ± 6.4 24.6 ± 10.0 24.6 ± 10.1 − 0.06 (− 1.64, 1.50) 0.93
Total cholesterol (mg/dL) 119.7 ± 31.0 122.5 ± 28.9 125.1 ± 36.6 125.6 ± 29.0 − 1.42 (− 8.00, 5.15) 0.66
LDL-cholesterol (mg/dL) 64.2 ± 34.1 67.3 ± 31.6 68.1 ± 26.0 66.4 ± 22.3 − 4.44 (− 10.32, 1.43) 0.13
HDL-cholesterol (mg/dL) 32.9 ± 6.0 32.2 ± 5.4 32.4 ± 6.0 34.5 ± 5.7 2.72 (0.89, 4.55) 0.005
Total-/HDL-cholesterol ratio 3.8 ± 1.4 3.9 ± 1.3 3.9 ± 0.9 3.7 ± 0.9 − 0.31 (− 0.53, − 0.09) 0.008
hs-CRP (mg/L) 5.5 ± 1.3 5.1 ± 1.5 5.9 ± 1.1 4.7 ± 0.8 − 0.68 (− 1.18, − 0.17) 0.01
NO (μmol/L) 30.1 ± 1.3 29.9 ± 4.1 27.9 ± 3.0 28.5 ± 3.1 1.31 (− 0.60, 3.24) 0.17
TAC (mmol/L) 920.3 ± 158.2 913.2 ± 167.5 950.9 ± 142.8 969.2 ± 127.5 26.16–2.01, 54.34) 0.06
GSH (μmol/L) 450.4 ± 111.9 440.5 ± 98.6 414.4 ± 80.8 482.9 ± 81.3 77.33 (56.11, 98.55) < 0.001
MDA (μmol/L) 3.0 ± 0.6 3.1 ± 0.7 2.9 ± 0.9 2.7 ± 0.8 − 0.27 (− 0.47, − 0.07) 0.009
Data are mean ± SD
1 BOutcome measures^ refers to the change in values of measures of interest between baseline and week 4. β (difference in the mean outcomes measures
between treatment groups (selenium group = 1 and placebo group = 0))
2 Obtained from multiple regression model (adjusted for baseline values of each biochemical variable, age, and baseline BMI)
FPG fasting plasma glucose, GSH total glutathione, HOMA-IR homeostasis model of assessment-estimated insulin resistance, hs-CRP high-sensitivity
C-reactive protein, MDA malondialdehyde, NO nitric oxide, QUICKI quantitative insulin sensitivity check index, TAC total antioxidant capacity
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Conclusions
Overall, our study supported that selenium supplementation
for 4 weeks to patients undergoing for CABG surgery had
beneficial effects on FPG, insulin, HOMA-IR, total-/HDL-
cholesterol ratio, HDL-cholesterol, hs-CRP, GSH, and MDA
levels, but did not affect other metabolic profiles.
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